An Investigational New Drug application for the Nectin4/TROP2 ADC is planned for submission to the U.S. Food and Drug Administration in ... played an integral role in its acquisition by Bristol Myers ...
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
The move reflects Novartis’ efforts to strengthen its radiopharmaceutical pipeline with an SSTR2 drug, following the lead of both Eli Lilly and Bristol Myers Squibb ... which the Food and Drug ...
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback